Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRELUDE: Pembrolizumab + Paclitaxel +/- Bevacizumab in Recurrent TNBC
NCT06976944Phase 2Recruiting
- Sponsor
- Yukinori Ozaki
- Start
- Jun 2025
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by Yukinori Ozaki. Started Jun 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06976944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976944.